QQ客服 官方微博 反馈留言

	The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell
	Chen, Xinyan; Chen, Yumei; Lin, Xueyan; Su, Shan; Hou, Xiaoman; Zhang, Qian; Tian, Yongjie
刊名	CURRENT PHARMACEUTICAL BIOTECHNOLOGY
	2018
卷号	19期号:6页码:506-513
关键词	Olaparib ovarian cancer SB202190 SP600125 MAPK anti-tumor
DOI	10.2174/1389201019666180713102656
URL标识	查看原文
公开日期	[db:dc_date_available]
内容类型	期刊论文
URI标识	http://www.corc.org.cn/handle/1471x/4572234
专题	山东大学
作者单位	Shandong Univ, Shandong Prov Hosp, Dept Obstet & Gynecol, 324 Jingwu Rd, Jinan 2
推荐引用方式 GB/T 7714	Chen, Xinyan,Chen, Yumei,Lin, Xueyan,et al. The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell[J]. CURRENT PHARMACEUTICAL BIOTECHNOLOGY,2018,19(6):506-513.
APA	Chen, Xinyan.,Chen, Yumei.,Lin, Xueyan.,Su, Shan.,Hou, Xiaoman.,...&Tian, Yongjie.(2018).The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell.CURRENT PHARMACEUTICAL BIOTECHNOLOGY,19(6),506-513.
MLA	Chen, Xinyan,et al."The Drug Combination of SB202190 and SP600125 Significantly Inhibit the Growth and Metastasis of Olaparib-resistant Ovarian Cancer Cell".CURRENT PHARMACEUTICAL BIOTECHNOLOGY 19.6(2018):506-513.

个性服务

查看访问统计

相关权益政策

暂无数据

收藏/分享

除非特别说明，本系统中所有内容都受版权保护，并保留所有权利。